Vaxcyte (PCVX) Competitors

Vaxcyte has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Moderna has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Vaxcyte has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Vaxcyte's return on equity.

In the previous week, Moderna had 3 more articles in the media than Vaxcyte. MarketBeat recorded 16 mentions for Moderna and 13 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.04 beat Moderna's score of 0.83 indicating that Vaxcyte is being referred to more favorably in the media.

Vaxcyte has higher earnings, but lower revenue than Moderna. Vaxcyte is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Vaxcyte presently has a consensus target price of $86.00, suggesting a potential upside of 57.51%. Moderna has a consensus target price of $40.00, suggesting a potential downside of 28.33%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts clearly believe Vaxcyte is more favorable than Moderna.

Vaxcyte has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, Insmed has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Vaxcyte has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Vaxcyte's return on equity of -32.51% beat Insmed's return on equity.

In the previous week, Vaxcyte and Vaxcyte both had 13 articles in the media. Insmed's average media sentiment score of 1.07 beat Vaxcyte's score of 1.04 indicating that Insmed is being referred to more favorably in the news media.

Vaxcyte currently has a consensus price target of $86.00, suggesting a potential upside of 57.51%. Insmed has a consensus price target of $209.35, suggesting a potential upside of 101.04%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Vaxcyte.

96.8% of Vaxcyte shares are held by institutional investors. 3.3% of Vaxcyte shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Vaxcyte has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 3.3% of Vaxcyte shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Vaxcyte presently has a consensus target price of $86.00, indicating a potential upside of 57.51%. BioNTech has a consensus target price of $129.13, indicating a potential upside of 39.67%. Given Vaxcyte's higher probable upside, equities research analysts plainly believe Vaxcyte is more favorable than BioNTech.

In the previous week, Vaxcyte had 8 more articles in the media than BioNTech. MarketBeat recorded 13 mentions for Vaxcyte and 5 mentions for BioNTech. BioNTech's average media sentiment score of 1.13 beat Vaxcyte's score of 1.04 indicating that BioNTech is being referred to more favorably in the news media.

Vaxcyte has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Vaxcyte's return on equity.

Vaxcyte has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Vaxcyte has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

Vaxcyte presently has a consensus target price of $86.00, suggesting a potential upside of 57.51%. Viatris has a consensus target price of $17.50, suggesting a potential downside of 2.02%. Given Vaxcyte's higher possible upside, equities research analysts clearly believe Vaxcyte is more favorable than Viatris.

In the previous week, Vaxcyte had 8 more articles in the media than Viatris. MarketBeat recorded 13 mentions for Vaxcyte and 5 mentions for Viatris. Vaxcyte's average media sentiment score of 1.04 beat Viatris' score of 0.37 indicating that Vaxcyte is being referred to more favorably in the media.

Vaxcyte has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Vaxcyte's return on equity.

Vaxcyte has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 3.3% of Vaxcyte shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Vaxcyte has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Viatris has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.